{"id":"gm2-klh-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (erythema, induration, pain)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine consists of the GM2 ganglioside (a tumor-associated carbohydrate antigen) conjugated to keyhole limpet hemocyanin (KLH) carrier protein. This conjugate is designed to elicit a humoral and cellular immune response against GM2-expressing tumors, particularly melanoma and other cancers. The immune system is trained to produce antibodies and T-cell responses that target and eliminate cancer cells bearing this antigen.","oneSentence":"GM2-KLH vaccine stimulates the immune system to recognize and attack cancer cells expressing the GM2 ganglioside antigen on their surface.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:12.119Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Melanoma (adjuvant setting)"},{"name":"Ovarian cancer"}]},"trialDetails":[{"nctId":"NCT01141491","phase":"PHASE2","title":"Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free","status":"COMPLETED","sponsor":"MabVax Therapeutics, Inc.","startDate":"2010-06","conditions":"Sarcoma","enrollment":136},{"nctId":"NCT01248273","phase":"PHASE1","title":"Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-11","conditions":"Fallopian Tubes, Ovarian Cancer, Peritoneal Cancer","enrollment":26},{"nctId":"NCT00030823","phase":"NA","title":"Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2001-03","conditions":"Breast Cancer","enrollment":14},{"nctId":"NCT00003357","phase":"PHASE1","title":"Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1998-01","conditions":"Breast Cancer","enrollment":9},{"nctId":"NCT00005052","phase":"PHASE3","title":"Vaccine Therapy in Treating Patients With Primary Stage II Melanoma","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1999-12","conditions":"Melanoma (Skin)","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GM2-KLH vaccine","genericName":"GM2-KLH vaccine","companyName":"European Organisation for Research and Treatment of Cancer - EORTC","companyId":"european-organisation-for-research-and-treatment-of-cancer-eortc","modality":"Biologic","firstApprovalDate":"","aiSummary":"GM2-KLH vaccine stimulates the immune system to recognize and attack cancer cells expressing the GM2 ganglioside antigen on their surface. Used for Melanoma (adjuvant setting), Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}